Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Chemo-free regimens continue for CLL

Stephan Stilgenbauer, MD, University of Ulm, Ulm, Germany, discusses the current landscape of chemotherapy-free regimens for chronic lymphocytic leukemia (CLL). The introduction of more targeted oral agents, such as ibrutinib and venetoclax, has led to these agents being tested in upfront studies compared to chemoimmunotherapy. Several large randomized trials doing just this were presented at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.